Liver transplant rejection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:24:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Liver transplant rejection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of QEL-001 (CAR T regulatory cell therapy) to prevent liver transplant rejection in patients with HLA-A2 positive donor organ https://clinicaltrials.eu/trial/study-on-qel-001-for-preventing-liver-transplant-rejection-in-patients-with-hla-a2-mismatch/ Wed, 29 Apr 2026 14:59:40 +0000 https://clinicaltrials.eu/trial/study-on-qel-001-for-preventing-liver-transplant-rejection-in-patients-with-hla-a2-mismatch/ This clinical study focuses on patients who have undergone liver transplantation and aims to prevent transplant rejection. The study evaluates a new treatment called QEL-001, which is made from the patient’s own modified immune cells (specifically T regulatory cells). These cells are specially engineered to recognize and target specific proteins found on the transplanted liver, potentially helping to prevent rejection of the organ.

The treatment involves collecting immune cells from the patient’s blood, modifying them in a laboratory to create QEL-001, and then returning them to the patient through intravenous injection. This is a type of personalized cell therapy where each treatment is specifically made for each individual patient using their own cells. The study will test a single dose of QEL-001 to determine if it is safe and well-tolerated by patients.

The study is designed for patients who received their liver transplant between 1 and 5 years ago from donors with specific tissue characteristics. The main purpose is to evaluate whether this treatment is safe and if it might allow patients to reduce or stop taking their regular anti-rejection medications. Patients will be monitored closely for any side effects and to see how well the treatment works in preventing rejection of the transplanted liver.

]]>